SQI Diagnostics (TSXV:SQD) - Cotización, noticias y análisis

Resumen de acción SQD

SQI Diagnostics Inc., a precision medicine company, discovers, develops, and commercializes rapid diagnostic testing services for healthcare providers, patients, and consumers worldwide.

Acerca de la empresa

SQD fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Recompensas

Análisis de riesgos

Los beneficios han disminuido un 20.5% al año en los últimos 5 años

No tiene una capitalización de mercado significativa (CA$6M)

Patrimonio neto negativo

Acciones altamente ilíquidas

+ 3 riesgos adicionales

Competidores de SQI Diagnostics Inc.

Scryb

CNSX:SCYB

CA$6.4m

Frequency Exchange

TSXV:FREQ

CA$5.5m

Evome Medical Technologies

TSXV:EVMT

CA$18.1m

Titan Medical

TSX:TMD

CA$6.3m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for SQI Diagnostics
Historical stock prices
Current Share Price	CA$0.015
52 Week High	CA$0.17
52 Week Low	CA$0.01
Beta	0.075
1 Month Change	0%
3 Month Change	0%
1 Year Change	-85.71%
3 Year Change	-93.88%
5 Year Change	-89.29%
Change since IPO	-99.23%

Noticias y actualizaciones recientes

Recent updates

If You Had Bought SQI Diagnostics (CVE:SQD) Stock A Year Ago, You Could Pocket A 246% Gain Today

Dec 22

Is SQI Diagnostics (CVE:SQD) Using Debt Sensibly?

Nov 17

Rentabilidad de los accionistas

	SQD	CA Medical Equipment	Mercado CA
7D	0%	2.3%	0.7%
1Y	-85.7%	-26.5%	4.9%

Rentabilidad vs. Industria: SQD obtuvo unos resultados inferiores a los del sector Canadian Medical Equipment , que el año pasado arrojó un rendimiento del -30%.

Rentabilidad vs. Mercado: SQD obtuvo unos resultados inferiores a los del mercado Canadian, que fue del 3.9% el año pasado.

Volatilidad de los precios

Is SQD's price volatile compared to industry and market?
SQD volatility
SQD Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	11.4%
Market Average Movement	9.0%
10% most volatile stocks in CA Market	18.1%
10% least volatile stocks in CA Market	3.0%

Precio estable de las acciones: El precio de las acciones de SQD ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de SQD en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1999	n/a	Andrew Morris	www.sqidiagnostics.com

Resumen de fundamentos de SQI Diagnostics Inc.

¿Cómo se comparan los beneficios e ingresos de SQI Diagnostics con su capitalización de mercado?
Estadísticas fundamentales de SQD
Capitalización bursátil	CA$6.11m
Beneficios(TTM)	-CA$19.14m
Ingresos (TTM)	CA$3.05m

2.0x

Ratio precio-ventas (PS)

-0.3x

Ratio precio-beneficio (PE)

¿Está SQD sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de SQD
Ingresos	CA$3.05m
Coste de los ingresos	CA$3.19m
Beneficio bruto	-CA$140.00k
Otros gastos	CA$19.00m
Beneficios	-CA$19.14m

Últimos beneficios comunicados

Mar 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.047
Margen bruto	-4.60%
Margen de beneficio neto	-628.51%
Ratio deuda/patrimonio	-103.3%

¿Cómo se ha desempeñado SQD a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción SQD

Recompensas

Análisis de riesgos

Competidores de SQI Diagnostics Inc.

CNSX:SCYB

CA$6.4m

TSXV:FREQ

CA$5.5m

TSXV:EVMT

CA$18.1m

TSX:TMD

CA$6.3m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

SQI Diagnostics Inc. Listing to Transfer to NEX Effective Feb. 20

Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc

SQI Diagnostics Expects its Common Shares to Continue to be Halted from Trading on Exchange and Ultimately Suspended and Delisted Following Completion of the Filing

SQI Diagnostics Inc. Announces Executive Changes

SQI Diagnostics Inc., Annual General Meeting, Jun 30, 2023

Second quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2022)

Recent updates

SQI Diagnostics Inc. Listing to Transfer to NEX Effective Feb. 20

Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc

SQI Diagnostics Expects its Common Shares to Continue to be Halted from Trading on Exchange and Ultimately Suspended and Delisted Following Completion of the Filing

SQI Diagnostics Inc. Announces Executive Changes

SQI Diagnostics Inc., Annual General Meeting, Jun 30, 2023

Second quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2022)

Insufficient new directors

First quarter 2023 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 1Q 2022)

SQI Diagnostics Inc., Annual General Meeting, Apr 05, 2023

Full year 2022 earnings released: CA$0.048 loss per share (vs CA$0.031 loss in FY 2021)

SQI Installs Two Rali-Dx Systems in Toronto Hospitals to Fight the Growing Respiratory Health Crisis in Emergency Departments

SQI Diagnostics Inc. announced that it expects to receive CAD 1 million in funding

SQI Diagnostics Inc. announced that it expects to receive CAD 2 million in funding from Federal Economic Development Agency for Southern Ontario

SQI Diagnostics Announces Health Canada Approval of RALI-Dx Severity Triage Test

Third quarter 2022 earnings released: CA$0.012 loss per share (vs CA$0.002 loss in 3Q 2021)

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

SQI Diagnostics (CVE:SQD) Has Debt But No Earnings; Should You Worry?

New York State Approves SQI Diagnostics' Exact Covid-19 Antibody Assay

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

SQI Diagnostics Systems Inc. signed a definitive agreement to acquire all of the assets underlying Precision Biomonitoring Inc businesses from Precision Biomonitoring Inc. for CAD 6.825 million

SQI Diagnostics Inc. announced that it expects to receive CAD 6 million in funding

Third quarter 2021 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 3Q 2020)

Is SQI Diagnostics (CVE:SQD) Weighed On By Its Debt Load?

FDA Stops Emergency Use Authorization Review of SQI Diagnostics Inc. RALI-Dx IL-6 Severity Triage Test for Covid-19 Patients

CEO & Director Robert Chioini has left the company

Second quarter 2021 earnings released: CA$0.011 loss per share (vs CA$0.009 loss in 2Q 2020)

Health Check: How Prudently Does SQI Diagnostics (CVE:SQD) Use Debt?

Independent Director recently sold CA$56k worth of stock

Are Insiders Buying SQI Diagnostics Inc. (CVE:SQD) Stock?

First quarter 2021 earnings released: CA$0.012 loss per share (vs CA$0.009 loss in 1Q 2020)

Director exercised options to buy CA$705k worth of stock.

Director recently bought CA$660k worth of stock

New 90-day high: CA$0.40

SQI Diagnostics Inc., Annual General Meeting, Mar 31, 2021

Full year 2020 earnings released: CA$0.032 loss per share (vs CA$0.045 loss in FY 2019)

Is SQI Diagnostics Inc. (CVE:SQD) Popular Amongst Insiders?

SQI Diagnostics Announces Patient Enrollment Begins for its COVID-19 HOME Antibody Test Clinical Study

New 90-day high: CA$0.28

Independent Director exercised options to buy CA$1.7m worth of stock.

If You Had Bought SQI Diagnostics (CVE:SQD) Stock A Year Ago, You Could Pocket A 246% Gain Today

Is SQI Diagnostics (CVE:SQD) Using Debt Sensibly?

Sqi Diagnostics Inc. Updates Clinical Progress on Novel Covid-19 Tests Under Development for U.S. Fda Regulatory Submission

Third quarter earnings released

SQI Diagnostics Inc. Announces Executive Changes

New 90-day high - CA$0.21

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de SQI Diagnostics Inc.

2.0x

-0.3x

Beneficios e Ingresos